Abstract 1276
Background
AFL targets VEGF-A, VEGF-B and PlGF. It is approved in combination with FOLFIRI for treatment of mCRC that is resistant to or has progressed after oxaliplatin-containing therapy.
Methods
QoLiTrap is an ongoing non-interventional study conducted in DACH region to evaluate Quality-of-life (QoL) in 1500 mCRC patients treated with AFL+FOLFIRI using the EORTC-QLQ C30 questionnaire at baseline and before every cycle.
Results
For this interim analysis according to age groups (≤ 65 and > 65 years / cut-off: 05 Dec 2017) 702 patients (mean age: 64.8 ± 9.9 yrs; 65.0% male, 50.9% with RAS mutation) who completed the baseline and at least 2 additional questionnaires were evaluated. 50% of patients each were ≤65 and >65 yrs old at therapy start. 86.3% and 85.8% of younger and older patients, respectively, had an ECOG of ≤ 1. A median of 7 cycles (range 1 – 65) was given to patients aged ≤65, patients >65 yrs received a median of 6 cycles (range 1 - 54). Mean global health scores at baseline was 55.6 for patients aged ≤65 yrs and 59.1 for patients aged >65 yrs. Mean score decreased slightly in both age groups. 48.4% of younger and 46.7% of older patients received study treatment as second line. More than 75% of patients in both age groups received prior anti-EGFR and / or bevacizumab (BEV) treatment. 89.5% of younger and 92.3% of older patients received prior palliative therapies or prior therapies during metastatic stage. Median PFS of patients pretreated with anti-EGFR or BEV only was 7.6 months (95% CI 3.7- ) and 7.0 months (95% CI 5.6- 8.5), respectively, for younger patients, and 9.4 months (95% CI 5.9- ) and 7.6 months (95% CI 5.8- 9.0), respectively, for older patients. Regarding evaluable patients pretreated with anti-EGFR and/or BEV 11.2% and 10.4% of age group ≤65 and >65 yrs, respectively, exhibited CR+PR.
Conclusions
This interim analysis showed that there are no obvious differences between age groups regarding previous treatment and efficacy in mCRC patients treated with AFL+FOLFIRI under routine conditions. Toxicity was in line with the known safety profile of the study medication. Supported by Sanofi-Aventis Deutschland GmbH.
Clinical trial identification
AIO-LQ-0113.
Legal entity responsible for the study
Sanofi-Aventis Deutschland GmbH.
Funding
Sanofi-Aventis Deutschland GmbH.
Editorial Acknowledgement
Medical writing assistence was provided by Claudia Lorenz-Schlüter (Alcedis GmbH Gießen, Germany), funded by Sanofi-Aventis Deutschland GmbH.
Disclosure
R.D. Hofheinz: Consulting fees, honorarium: Sanofi, Merck, Amgen, Roche, Servier; Grant received/grants pending: Sanofi, Merck, Amgen, Roche. H-G. Derigs: Sponsoring congresses: Roche, Jannsen, Celgene, BMS. R. von Moos: Advisory board: Amgen Roche, Merck und Sanofi; Speaker Honoraria: Roche, Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract